Moderna, COVID-19 and Europe

Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High
Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned increasingly positive following the company’s announcement of a new vaccine tender agreement.
Moderna Secures European Contract For Covid-19 Vaccine
Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to enhance healthcare delivery.
Moderna extends gains as EU offers COVID vaccine contract
Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, Norway, and North Macedonia. Read more here.
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats
Moderna Receives EU Tender Order for Covid-19 Vaccine
Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was among the world's best-selling medicines in the depths of the pandemic in 2021.
Moderna awarded tender for COVID-19 vaccine in EU, Norway and North Macedonia
Moderna (MRNA) announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union, Norway and North
Moderna secures EU deal for mRNA COVID-19 vaccine supply
The press release also contained forward-looking statements, cautioning that these are not guarantees and are subject to risks, uncertainties, and other factors that could cause actual results to differ from expectations.
Investor's Business Daily on MSN11h
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots
Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.
From Covid to Norovirus: Moderna’s mRNA Tech Takes on Stomach Flu
The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Copyright 2025 The Associated Press. All Rights Reserved. A local resident receives the Moderna COVID-19 vaccine shot at ...
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna’s stock tumbles to post-COVID lows after revenue outlook disappoints
Moderna’s stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
Investor's Business Daily on MSN1d
Is Larry Ellison Moderna's Saving Grace? Is Moderna Stock Now A Buy?
Moderna stock has fallen over the past four years, but shares got a boost on positive comments about AI. Is MRNA stock a buy ...